Cargando…

563. Experience of a Private Hospital in the Treatment of COVID-19 Pneumonia in Veracruz, Mexico

BACKGROUND: Large mortality rates have been reported in the Mexican public health system, however in the experiences of private hospitals that have resources and infrastructure this is lower compared to the national average. METHODS: Descriptive and retrospective study. Adult patients treated for pn...

Descripción completa

Detalles Bibliográficos
Autores principales: Del Carpio-Orantes, Luis, Márquez-Rodriguez, Luis Alberto, García-Pérez, José Luis, Rodríguez-Santos, Christian Alberto, Llaven-Velázquez, Carlos Yahir, Gutiérrez-Martínez, Eduardo, Lucho-Morales, Anel Concepción, Mendoza-Hernández, Juan Carlos, García-Ortíz, Jorge José, Medrano-Rios, Luis Jaime, Ruiz-Castro, Enrique, Ortiz-Hernández, Manuel Alejandro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8690549/
http://dx.doi.org/10.1093/ofid/ofab466.761
_version_ 1784618665449095168
author Del Carpio-Orantes, Luis
Márquez-Rodriguez, Luis Alberto
García-Pérez, José Luis
Rodríguez-Santos, Christian Alberto
Llaven-Velázquez, Carlos Yahir
Gutiérrez-Martínez, Eduardo
Lucho-Morales, Anel Concepción
Mendoza-Hernández, Juan Carlos
García-Ortíz, Jorge José
Medrano-Rios, Luis Jaime
Ruiz-Castro, Enrique
Ortiz-Hernández, Manuel Alejandro
author_facet Del Carpio-Orantes, Luis
Márquez-Rodriguez, Luis Alberto
García-Pérez, José Luis
Rodríguez-Santos, Christian Alberto
Llaven-Velázquez, Carlos Yahir
Gutiérrez-Martínez, Eduardo
Lucho-Morales, Anel Concepción
Mendoza-Hernández, Juan Carlos
García-Ortíz, Jorge José
Medrano-Rios, Luis Jaime
Ruiz-Castro, Enrique
Ortiz-Hernández, Manuel Alejandro
author_sort Del Carpio-Orantes, Luis
collection PubMed
description BACKGROUND: Large mortality rates have been reported in the Mexican public health system, however in the experiences of private hospitals that have resources and infrastructure this is lower compared to the national average. METHODS: Descriptive and retrospective study. Adult patients treated for pneumonia due COVID-19 from April to December 2020 are entered into the study. Its general characteristics such as gender and age, comorbidities, influenza vaccination history, clinical characterization, laboratory and tomographic diagnosis of sars cov2 pneumonia are studied, as well as the drug and oxygen therapy treatments received and finally, its evolution and clinical outcome. RESULTS: 132 patients were studied, of which 51% were female. The main age groups affected were 65 and over (43.9%), 50-59 years (20.4%) and 25-44 years (16.6%). The main comorbidities found were: arterial hypertension (43.9%), Diabetes mellitus 2 (33.3%), heart disease (11.3%) and obesity (10.6%). 95.4% of the patients were not vaccinated against influenza. The main symptoms reported were: fever (92%), cough (87%), dyspnea (76%) and headache (52%). The diagnosis was confirmed with RT-PCR in 63%, reporting negative RT-PCR in 36%; the antigen test was positive in 1%. Regarding the findings of the chest computed tomography, CORADS 5 was reported in 30%, CORADS 6 in 3% and CORADS 4 in 20%. The main treatments used in patients with severe inflammatory pneumonia were: steroids (98%), enoxaparin (100%), tocilizumab (20%), baricitinib (60%), direct oral anticoagulants (10%), fibroquel (5%). 60% were treated with a combination of two or more drugs. The main oxygenation contributions were: 20% nasal tips - mask/reservoir, 60% high flow nasal cannula, 20% mechanical ventilation. In 95% the prone position was indicated. Regarding the clinical evolution, 65.1% were towards improvement, 17.4% died, 12.1% requested transfer to another unit and 5.3% requested voluntary discharge. Overall mortality was 17%. Medications in ICU [Image: see text] Ventilation strategies [Image: see text] CONCLUSION: A hospital strategy that has the necessary resources and infrastructure as well as openness to the use of medication with emergency approvals for its use or off-label indications, can help limit morbidity and mortality in vulnerable populations and manifest risk factors such as Mexican population DISCLOSURES: All Authors: No reported disclosures
format Online
Article
Text
id pubmed-8690549
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-86905492022-01-05 563. Experience of a Private Hospital in the Treatment of COVID-19 Pneumonia in Veracruz, Mexico Del Carpio-Orantes, Luis Márquez-Rodriguez, Luis Alberto García-Pérez, José Luis Rodríguez-Santos, Christian Alberto Llaven-Velázquez, Carlos Yahir Gutiérrez-Martínez, Eduardo Lucho-Morales, Anel Concepción Mendoza-Hernández, Juan Carlos García-Ortíz, Jorge José Medrano-Rios, Luis Jaime Ruiz-Castro, Enrique Ortiz-Hernández, Manuel Alejandro Open Forum Infect Dis Poster Abstracts BACKGROUND: Large mortality rates have been reported in the Mexican public health system, however in the experiences of private hospitals that have resources and infrastructure this is lower compared to the national average. METHODS: Descriptive and retrospective study. Adult patients treated for pneumonia due COVID-19 from April to December 2020 are entered into the study. Its general characteristics such as gender and age, comorbidities, influenza vaccination history, clinical characterization, laboratory and tomographic diagnosis of sars cov2 pneumonia are studied, as well as the drug and oxygen therapy treatments received and finally, its evolution and clinical outcome. RESULTS: 132 patients were studied, of which 51% were female. The main age groups affected were 65 and over (43.9%), 50-59 years (20.4%) and 25-44 years (16.6%). The main comorbidities found were: arterial hypertension (43.9%), Diabetes mellitus 2 (33.3%), heart disease (11.3%) and obesity (10.6%). 95.4% of the patients were not vaccinated against influenza. The main symptoms reported were: fever (92%), cough (87%), dyspnea (76%) and headache (52%). The diagnosis was confirmed with RT-PCR in 63%, reporting negative RT-PCR in 36%; the antigen test was positive in 1%. Regarding the findings of the chest computed tomography, CORADS 5 was reported in 30%, CORADS 6 in 3% and CORADS 4 in 20%. The main treatments used in patients with severe inflammatory pneumonia were: steroids (98%), enoxaparin (100%), tocilizumab (20%), baricitinib (60%), direct oral anticoagulants (10%), fibroquel (5%). 60% were treated with a combination of two or more drugs. The main oxygenation contributions were: 20% nasal tips - mask/reservoir, 60% high flow nasal cannula, 20% mechanical ventilation. In 95% the prone position was indicated. Regarding the clinical evolution, 65.1% were towards improvement, 17.4% died, 12.1% requested transfer to another unit and 5.3% requested voluntary discharge. Overall mortality was 17%. Medications in ICU [Image: see text] Ventilation strategies [Image: see text] CONCLUSION: A hospital strategy that has the necessary resources and infrastructure as well as openness to the use of medication with emergency approvals for its use or off-label indications, can help limit morbidity and mortality in vulnerable populations and manifest risk factors such as Mexican population DISCLOSURES: All Authors: No reported disclosures Oxford University Press 2021-12-04 /pmc/articles/PMC8690549/ http://dx.doi.org/10.1093/ofid/ofab466.761 Text en © The Author(s) 2021. Published by Oxford University Press on behalf of Infectious Diseases Society of America. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Poster Abstracts
Del Carpio-Orantes, Luis
Márquez-Rodriguez, Luis Alberto
García-Pérez, José Luis
Rodríguez-Santos, Christian Alberto
Llaven-Velázquez, Carlos Yahir
Gutiérrez-Martínez, Eduardo
Lucho-Morales, Anel Concepción
Mendoza-Hernández, Juan Carlos
García-Ortíz, Jorge José
Medrano-Rios, Luis Jaime
Ruiz-Castro, Enrique
Ortiz-Hernández, Manuel Alejandro
563. Experience of a Private Hospital in the Treatment of COVID-19 Pneumonia in Veracruz, Mexico
title 563. Experience of a Private Hospital in the Treatment of COVID-19 Pneumonia in Veracruz, Mexico
title_full 563. Experience of a Private Hospital in the Treatment of COVID-19 Pneumonia in Veracruz, Mexico
title_fullStr 563. Experience of a Private Hospital in the Treatment of COVID-19 Pneumonia in Veracruz, Mexico
title_full_unstemmed 563. Experience of a Private Hospital in the Treatment of COVID-19 Pneumonia in Veracruz, Mexico
title_short 563. Experience of a Private Hospital in the Treatment of COVID-19 Pneumonia in Veracruz, Mexico
title_sort 563. experience of a private hospital in the treatment of covid-19 pneumonia in veracruz, mexico
topic Poster Abstracts
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8690549/
http://dx.doi.org/10.1093/ofid/ofab466.761
work_keys_str_mv AT delcarpioorantesluis 563experienceofaprivatehospitalinthetreatmentofcovid19pneumoniainveracruzmexico
AT marquezrodriguezluisalberto 563experienceofaprivatehospitalinthetreatmentofcovid19pneumoniainveracruzmexico
AT garciaperezjoseluis 563experienceofaprivatehospitalinthetreatmentofcovid19pneumoniainveracruzmexico
AT rodriguezsantoschristianalberto 563experienceofaprivatehospitalinthetreatmentofcovid19pneumoniainveracruzmexico
AT llavenvelazquezcarlosyahir 563experienceofaprivatehospitalinthetreatmentofcovid19pneumoniainveracruzmexico
AT gutierrezmartinezeduardo 563experienceofaprivatehospitalinthetreatmentofcovid19pneumoniainveracruzmexico
AT luchomoralesanelconcepcion 563experienceofaprivatehospitalinthetreatmentofcovid19pneumoniainveracruzmexico
AT mendozahernandezjuancarlos 563experienceofaprivatehospitalinthetreatmentofcovid19pneumoniainveracruzmexico
AT garciaortizjorgejose 563experienceofaprivatehospitalinthetreatmentofcovid19pneumoniainveracruzmexico
AT medranoriosluisjaime 563experienceofaprivatehospitalinthetreatmentofcovid19pneumoniainveracruzmexico
AT ruizcastroenrique 563experienceofaprivatehospitalinthetreatmentofcovid19pneumoniainveracruzmexico
AT ortizhernandezmanuelalejandro 563experienceofaprivatehospitalinthetreatmentofcovid19pneumoniainveracruzmexico